

A severe PRDC challenge and the effect of a trivalent PRDC vaccine for PCV2, *Mhp* and PRRS

R. Philips¹, E. Fano¹, E. Schmaling², R. Edler²

¹Boehringer Ingelheim Vetmedica, Inc., MO, USA;

²Health Management Center (HMC), Field Research Services, BIVI, Ames, Iowa

INTRODUCTION

Porcine respiratory disease complex (PRDC) is a significant challenge for the global swine industry. PRDC includes both viral and bacterial respiratory pathogens, mainly Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), Porcine Circovirus type 2 (PCV2), *Mycoplasma hyopneumoniae* (*Mhp*) and secondary bacterial agents. Vaccine derived immune protection against clinical disease associated with PRDC pathogens is one control intervention. The purpose of this controlled-experimental study was to evaluate pigs vaccinated with 3FLEX[®] (a trivalent PCV2, *Mhp* and PRRS vaccine) compared to a non-vaccinated group following a severe PRDC challenge.

MATERIALS AND METHODS

Group 1 was a non-vaccinated challenged control group of 20 pigs. Group 2 was a 3FLEX[®] vaccinated and challenged group of 20 pigs. Groups 1 and 2 were simultaneously inoculated with PCV2d (intranasal and intramuscular), *Mhp* strain 232 (intra tracheal) and PRRSV strain SDSU-73 (intranasal and intramuscular). The challenge incorporates a well referenced virulent heterologous PRRSV isolate, a contemporary virulent PCV2 field isolate, given simultaneously with *Mhp*, representing a severe PRDC challenge.

Table 1: Post-challenge clinical observations

Clinical Observation	Treatment		P-Value
	Challenge Control (Clinical observations/ Total events)	3FLEX [®] (Clinical observations/ Total events)	
Respiratory	268/530 (50.57%)	205/559 (36.67%)	<0.0001
Behavior	217/530 (40.94%)	49/559 (8.77%)	<0.0001

Numbers shown in this table are representative of the total number of observations and events of the 20 animals per group. Analyzed using Pearson's chi-square.

Table 2: Least square means for percent lung lesion by treatment

Treatment Group	Mean	SD*	SE**	Lower 95%	Upper 95%
Challenge Control	43.21 ^a	16.87	3.29	36.55	49.87
3FLEX [®]	22.81 ^b	12.19	3.29	16.15	29.47

^{ab} Means Differ <0.05 Wilcoxon rank sums test

* SD = standard deviation

** SE = standard error

Table 3: Summary inferential statistics for PCV2 variables. Improvement compared to challenge controls

Variable	Reduction compared to challenge control	P-Value
Tonsil Depletion	Yes	0.073
LN Depletion	Yes	0.038
Tonsil IHC	Yes	0.000
LN IHC	Yes	0.001
Lung IHC	Yes	0.01
Viremia %	Yes	0.01
Viremia CT	Yes	0.00001



RESULTS

Significant differences ($P < 0.05$) in respiratory clinical signs, gross lung lesions and PCV2 parameters (Lymphoid depletion, IHC and Viremia) are shown in Tables 1, 2 and 3. A reduction in post-challenge PRRSV viremia (Figure 1), and increased average daily weight gain was demonstrated (Table 4) in vaccinates compared to non-vaccinates. Based on clinical, pathological and production results from this study a severe PRDC challenge was successfully accomplished.

As stated in the introduction, the purpose of this controlled-experimental study was to evaluate pigs vaccinated with 3FLEX® (a trivalent PCV2, *Mhp* and PRRS vaccine) compared to a non-vaccinated group following a severe PRDC challenge.

DISCUSSION AND CONCLUSION

The results of this trial demonstrate that 3FLEX® provides protection to pigs simultaneously challenged with PRRS, PCV2 and *Mhp*. In the face of severe PRDC challenge, use of a trivalent vaccine mixture is an option for mitigation of the biologic impact of PRDC.

Table 4: Summary descriptive statistics for growth performance from day 28 (challenge) to 56 (end of the study). Average Daily Gain, lbs.

Treatment Group	Response Variable	Mean	SD*	SE**	Lower 95% CI	Upper 95% CI	CV***
Challenge control	Day 28 to 56 ADG, lbs./day.	0.60	0.47	0.12	0.35	0.86	78.43
3FLEX®		1.20	0.34	0.07	1.05	1.36	27.82
Challenge control	Day 0 to 56 ADG, lbs./day.	0.97	0.24	0.06	0.84	1.10	24.87
3FLEX®		1.23	0.21	0.05	1.13	1.33	17.11

* SD = standard deviation
 ** SE = standard error
 *** CV = coefficient of variation

Figure 1: Percentage positive and average CT for PRRS PCR results

